FORM 4	4
--------	---

Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Pe MCLAUGHLIN JOHN	2. Issuer Name <b>and</b> Ticker or Trading Symbol Sonoma Pharmaceuticals, Inc. [SNOA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) C/O SONOMA PHARMACEU INC., 1129 N. MCDOWELL BI	3. Date of Earliest Transaction (Month/Day/Year) 05/30/2018						Officer (give title below)	Other (specify b	pelow)		
(Street) PETALUMA, CA 94954	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Ber						ired, Disposed of, or Beneficially	ficially Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if	Code (Instr. 8)		(A) or Disposed of (D)		)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Form:	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock, \$0.0001 par value per share	05/30/2018		А		1,781	А	<u>(1)</u>	48,728	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

( <i>e.g.</i> , puts, calls, warrants, options, convertible securities)														
Security (Instr. 3)	Conversion	Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction Code	5. Ni of	umber vative rities uired or osed	6. Date Exercisable and Expiration Date (Month/Day/Year)		Date Exercisable d Expiration Date Ionth/Day/Year) 7. Title and Amount of Underlying		Derivative Security (Instr. 5)	re Derivative Ownership Securities Form of Beneficially Derivative		Beneficial Ownership (Instr. 4)
					À, an	d 5)	Date	Expiration Date	Title	Amount or Number			<b>``</b>	
				Code V	(A)		Exercisable	Date		of Shares				

## **Reporting Owners**

Describe Operation News (Address	Relationships					
<b>Reporting Owner Name / Address</b>	Director	10% Owner	Officer	Other		
MCLAUGHLIN JOHN C/O SONOMA PHARMACEUTICALS, INC. 1129 N. MCDOWELL BLVD. PETALUMA, CA 94954	Х					

### **Signatures**

/s/ Robert Miller as attorney-in-fact	06/01/2018	
**Signature of Reporting Person	Date	

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.